

## About Zomedica

Based in Ann Arbor, Michigan, Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.

## Veterinary Customers

Companion animal veterinary medicine is a unique opportunity compared to human medicine:

- **Veterinarians:** serve as both clinician and pharmacist.
- **Payers:** cost of care is often not subsidized by third-party payers, i.e. insurance.
- **Patients:** multiple species of variable sizes.
- **Pharmacy:** rely heavily on unapproved animal drugs, i.e. approved human drugs used off-label or compounded drugs.

Moreover, clinical veterinarians are dealing with compassion fatigue, margin pressures, disproportionate student debt and other factors that affect their professional and personal satisfaction. Statistics show an alarmingly high risk of suicide in the veterinary profession, possibly attributed to those challenges.

## Stock Information

Exchange Ticker – FX	NYSE American: ZOM US\$	TSX-V: ZOM CDN\$
Price @ 7/18/18	\$2.12	\$3.05
52-Week Range	\$1.75 – \$2.98	\$2.21 – \$3.73
Avg. Daily Volume	98,600	8,600

## Capitalization Table

Cash @ 3/31/18*	\$3.1 MM
Working Capital @ 3/31/18	\$2.7 MM
Available Unsecured Loan Facility	\$5.0 MM
Common Shares @ 5/14/18	
Basic	92.6 MM
Options	6.3 MM
<b>Market Capitalization @ US\$2.12, 7/18/18</b>	<b>\$200 MM</b>

\*On June 28, 2018, Zomedica completed an interim closing of a private offering issuing an aggregate of 1.9 MM Common Shares for gross proceeds of \$4.0 MM.

**Industry**  
Animal health/biotechnology

**Target Species**  
Dogs, cats & horses

**Target Customers**  
Clinical veterinarians

**Fiscal Year-End**  
December 31

**Capital Stock**  
\$20 million

**Number of Employees**  
21 FTEs

**Address**  
100 Phoenix Drive, Ste. 190  
Ann Arbor, MI 48108

**Media Contact**  
+1 415.521.0398  
[news@zomedica.com](mailto:news@zomedica.com)

**Investor Relations Contact**  
PCG Advisory Group  
+1 646.863.6519  
[ksmith@pcgadvisory.com](mailto:ksmith@pcgadvisory.com)

**ZOM**  
LISTED  
NYSE AMERICAN

**TMX** | TSX Venture  
Exchange




## Pipeline: Novel Diagnostics + Innovative Therapeutics

Zomedica has entered into a license and supply agreement with Celsee, Inc. (“Celsee”) to develop and market Celsee’s liquid biopsy platform for application as a veterinary cancer diagnostic. Using Celsee’s liquid biopsy platform, Zomedica initially intends to develop and market ZM-017, a non-invasive diagnostic assay or blood test that helps veterinarians diagnose cancer in canines.

Zomedica has entered into a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. (“Seraph”) to develop and market a novel, veterinary pathogen detection system in the form of an innovative point-of-care diagnostic instrument, referred to as ZM-020.

Zomedica’s therapeutic pipeline is based on human approved drug formulations or compounding pharmacy formulations that veterinarians are already using to treat their patients. Zomedica’s therapeutic candidates are being formulated for animal physiology, tested for safety and efficacy, and submitted to the FDA Center for Veterinary Medicine (FDA-CVM) for approval. Zomedica’s lead therapeutic candidates are identified below.



Zomedica is actively looking to expand its diagnostic pipeline through collaborations, in-licensing, and other strategic relationships involving technologies appropriate for the veterinary medicine space.